161 related articles for article (PubMed ID: 22606272)
1. Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen.
Bordeaux JM; Cheng H; Welsh AW; Haffty BG; Lannin DR; Wu X; Su N; Ma XJ; Luo Y; Rimm DL
PLoS One; 2012; 7(5):e36559. PubMed ID: 22606272
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
Kim C; Tang G; Pogue-Geile KL; Costantino JP; Baehner FL; Baker J; Cronin MT; Watson D; Shak S; Bohn OL; Fumagalli D; Taniyama Y; Lee A; Reilly ML; Vogel VG; McCaskill-Stevens W; Ford LG; Geyer CE; Wickerham DL; Wolmark N; Paik S
J Clin Oncol; 2011 Nov; 29(31):4160-7. PubMed ID: 21947828
[TBL] [Abstract][Full Text] [Related]
3. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
4. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
5. The promoter C specific ERalpha isoform is associated with tamoxifen outcome in breast cancer.
Amaral S; Schroth W; Kugler S; Fritz P; Simon W; Brauch H
Breast Cancer Res Treat; 2009 Nov; 118(2):323-31. PubMed ID: 19011961
[TBL] [Abstract][Full Text] [Related]
6. MEL-18 loss mediates estrogen receptor-α downregulation and hormone independence.
Lee JY; Won HY; Park JH; Kim HY; Choi HJ; Shin DH; Kang JH; Woo JK; Oh SH; Son T; Choi JW; Kim S; Kim HY; Yi K; Jang KS; Oh YH; Kong G
J Clin Invest; 2015 May; 125(5):1801-14. PubMed ID: 25822021
[TBL] [Abstract][Full Text] [Related]
7. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
8. Estrogen Receptor-α Quantification in Breast Cancer: Concordance Between Immunohistochemical Assays and mRNA-In Situ Hybridization for ESR1 Gene.
Thomsen C; Nielsen S; Nielsen BS; Pedersen SH; Vyberg M
Appl Immunohistochem Mol Morphol; 2020; 28(5):347-353. PubMed ID: 30920963
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG).
Pentheroudakis G; Kotoula V; Eleftheraki AG; Tsolaki E; Wirtz RM; Kalogeras KT; Batistatou A; Bobos M; Dimopoulos MA; Timotheadou E; Gogas H; Christodoulou C; Papadopoulou K; Efstratiou I; Scopa CD; Papaspyrou I; Vlachodimitropoulos D; Linardou H; Samantas E; Pectasides D; Pavlidis N; Fountzilas G
PLoS One; 2013; 8(7):e70634. PubMed ID: 23923010
[TBL] [Abstract][Full Text] [Related]
10. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
[TBL] [Abstract][Full Text] [Related]
12. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
[TBL] [Abstract][Full Text] [Related]
13. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
[TBL] [Abstract][Full Text] [Related]
15. Genomic index of sensitivity to endocrine therapy for breast cancer.
Symmans WF; Hatzis C; Sotiriou C; Andre F; Peintinger F; Regitnig P; Daxenbichler G; Desmedt C; Domont J; Marth C; Delaloge S; Bauernhofer T; Valero V; Booser DJ; Hortobagyi GN; Pusztai L
J Clin Oncol; 2010 Sep; 28(27):4111-9. PubMed ID: 20697068
[TBL] [Abstract][Full Text] [Related]
16. Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
Singer CF; ; Holst F; Steurer S; Burandt EC; Lax SF; Jakesz R; Rudas M; Stöger H; Greil R; ; Sauter G; Filipits M; ; Simon R; Gnant M;
Clin Cancer Res; 2022 Sep; 28(18):4112-4120. PubMed ID: 35920686
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor alpha gene ESR1 amplification may predict endocrine therapy responsiveness in breast cancer patients.
Tomita S; Zhang Z; Nakano M; Ibusuki M; Kawazoe T; Yamamoto Y; Iwase H
Cancer Sci; 2009 Jun; 100(6):1012-7. PubMed ID: 19320640
[TBL] [Abstract][Full Text] [Related]
18. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers.
O'Neill PA; Davies MP; Shaaban AM; Innes H; Torevell A; Sibson DR; Foster CS
Br J Cancer; 2004 Nov; 91(9):1694-702. PubMed ID: 15477865
[TBL] [Abstract][Full Text] [Related]
19. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
20. Amplification of ESR1 may predict resistance to adjuvant tamoxifen in postmenopausal patients with hormone receptor positive breast cancer.
Nielsen KV; Ejlertsen B; Müller S; Møller S; Rasmussen BB; Balslev E; Lænkholm AV; Christiansen P; Mouridsen HT
Breast Cancer Res Treat; 2011 Jun; 127(2):345-55. PubMed ID: 20556506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
